Bottom‐Up Extrusion‐Based Biofabrication of the Osteoid Niche

Abstract

AbstractBone regeneration remains a clinical challenge given the transplantation incidence rate and the associated economic burden. Bottom‐up osteoid tissue engineering has the potential to offer an alternative approach to current clinical solutions that suffer from various drawbacks. In this paper, deposition‐based bioprinting is exploited while the effect is explored of both the crosslinking mechanism (gelatin methacryloyl (GelMA) versus gelatin norbornene (DS 91) crosslinked with thiolated gelatin (GelNBSH)) and the degree of substitution (GelNBSH versus norbornene‐norbornene‐modified gelatin (DS 169) crosslinked with thiolated gelatin (GelNBNBSH)) on the presented biophysical cues as well as on the osteogenic differentiation. The incorporation of tris(2‐carboxyethyl)phosphine (TCEP) to the step‐growth inks allows the production of reproducible and biocompatible scaffolds based on thiol‐ene chemistry. Dental pulp stem cell encapsulation in GelNBNBSH biofabricated constructs shows a favorable response due to the combination of its stress relaxation and substrate rigidity (bulk compressive modulus of 11–30 kPa) as reflected by a sevenfold increase in calcium production compared to the tissue engineering standard GelMA. This work is the first to exploit a controlled biocompatible and cell‐interactive thiolated macromolecular crosslinker (GelSH + TCEP) allowing the extrusion‐based biofabrication of low concentration (5 w/v%) modified osteogenic gelatin‐based inks (GelNBNBSH + TCEP).